Concepedia

Kevin Roehle

KR

Statistics

Publications

5

Citations

362

H-Index

5

Active since

2015

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Massachusetts General Hospital

Novartis (United States)

Kevin Roehle is an author at Dana-Farber Cancer Institute specializing in oncology, immune checkpoint inhibitors, and cancer immunotherapy.

ORCID

Publications per year

2015–2023

5

Publications

5

EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer

Katherine L. Morel, Anjali V. Sheahan, Deborah L. Burkhart et al. · Nature Cancer · 2021 · 241 citations · Full text

, , +12

cIAP1/2 antagonism eliminates MHC class I–negative tumors through T cell–dependent reprogramming of mononuclear phagocytes

Kevin Roehle, Qiang Li, Katherine S. Ventre et al. · Science Translational Medicine · 2021 · 66 citations · Full text

, , +17

Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer

Courtney T. Stump, Kevin Roehle, Nataly Manjarrez‐Orduño et al. · Open Biology · 2021 · 23 citations · Full text

, , +17

HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy

Janet K. Peper-Gabriel, H. Bösmüller, Heiko Schuster et al. · OncoImmunology · 2015 · 19 citations · Full text

, , +17

cIAP1/2 Antagonism Induces Antigen-Specific T Cell–Dependent Immunity

Katherine S. Ventre, Kevin Roehle, Elisa Bello et al. · The Journal of Immunology · 2023 · 13 citations · Full text

, , +17

1–5 of 5